Soluble biological markers in osteoarthritis
In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-09-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X211040300 |
id |
doaj-42d186daa3504822bbcdace1beab3d63 |
---|---|
record_format |
Article |
spelling |
doaj-42d186daa3504822bbcdace1beab3d632021-09-30T21:34:29ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182021-09-011310.1177/1759720X211040300Soluble biological markers in osteoarthritisJean-Charles RousseauRoland ChapurlatPatrick GarneroIn recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks.https://doi.org/10.1177/1759720X211040300 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jean-Charles Rousseau Roland Chapurlat Patrick Garnero |
spellingShingle |
Jean-Charles Rousseau Roland Chapurlat Patrick Garnero Soluble biological markers in osteoarthritis Therapeutic Advances in Musculoskeletal Disease |
author_facet |
Jean-Charles Rousseau Roland Chapurlat Patrick Garnero |
author_sort |
Jean-Charles Rousseau |
title |
Soluble biological markers in osteoarthritis |
title_short |
Soluble biological markers in osteoarthritis |
title_full |
Soluble biological markers in osteoarthritis |
title_fullStr |
Soluble biological markers in osteoarthritis |
title_full_unstemmed |
Soluble biological markers in osteoarthritis |
title_sort |
soluble biological markers in osteoarthritis |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Musculoskeletal Disease |
issn |
1759-7218 |
publishDate |
2021-09-01 |
description |
In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks. |
url |
https://doi.org/10.1177/1759720X211040300 |
work_keys_str_mv |
AT jeancharlesrousseau solublebiologicalmarkersinosteoarthritis AT rolandchapurlat solublebiologicalmarkersinosteoarthritis AT patrickgarnero solublebiologicalmarkersinosteoarthritis |
_version_ |
1716862770902728704 |